ASCO GU 2018: Adjuvant radiotherapy and chemotherapy in node-positive prostate cancer

The use adjuvant treatment for patients with high risk or node-positive prostate cancer patients remains controversial despite level 1 evidence demonstrating a benefit. The controversy revolves around the risk of over treatment in addition to the lack of evidence demonstrating the superiority of adjuvant over early salvage therapy.
Uro Today

Leave a Reply

  • (will not be published)

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>